From Wikipedia, the free encyclopedia
Jump to: navigation, search
Combination of
Emtricitabine Nucleoside analog reverse-transcriptase inhibitor
Rilpivirine Non-nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil fumarate Nucleoside analog reverse-transcriptase inhibitor
Clinical data
Legal status
Routes Oral
CAS number  YesY
ATC code J05AR08
 YesY (what is this?)  (verify)

Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV.[1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011 (Eviplera),[2] for patients who have not previously been treated for HIV.[3] It is available as a once-a-day single tablet.